Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial

Files in this Data Supplement:

This Article

  1. Diabetes November 2013 vol. 62 no. 11 3766-3774
  1. » Supplementary Data